Cargando…

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer

Diverse proinflammatory biomarkers and oxidative stress are strongly associated with advanced epithelial ovarian cancer (EOC). Objective. To determine the behavior of markers of oxidative stress and inflammation in plasma and ascites fluid in patients with platinum-sensitive, platinum-resistant, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cantón-Romero, Juan Carlos, Miranda-Díaz, Alejandra Guillermina, Bañuelos-Ramírez, Jose Luis, Carrillo-Ibarra, Sandra, Sifuentes-Franco, Sonia, Castellanos-González, José Alberto, Rodríguez-Carrizalez, Adolfo Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564108/ https://www.ncbi.nlm.nih.gov/pubmed/28848618 http://dx.doi.org/10.1155/2017/2873030

Ejemplares similares

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
por: Cui, Qingli, et al.
Publicado: (2021)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
por: Sayal, Karen, et al.
Publicado: (2015)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
por: Cottrill, Hope, et al.
Publicado: (2018)

Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer
por: Gulia, Seema, et al.
Publicado: (2020)

Platinum
Publicado: (1860)

Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study
por: Chen, Wei, et al.
Publicado: (2020)

Erratum: Thermal Expansion of Platinum and Platinum-Rhodium Alloys
por: Edsinger, RE, et al.
Publicado: (2014)

A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer
por: Carroll, Molly J., et al.
Publicado: (2022)

Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition
por: Huang, Hongbiao, et al.
Publicado: (2017)

Predicting response to platinum and non-platinum drugs through bioluminescence resonance energy transfer (BRET) based bio-molecular interactions in platinum resistant epithelial ovarian cancer
por: Bishnu, Aniketh, et al.
Publicado: (2021)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas
por: Arias-Diaz, Andrea Estrella, et al.
Publicado: (2023)

Platinum Amalgam
por: Chase,
Publicado: (1872)

About Platinum
Publicado: (1890)

The Shortage of Platinum
Publicado: (1916)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Platinum-Based Nanoformulations for Glioblastoma Treatment: The Resurgence of Platinum Drugs?
por: Alfonso-Triguero, Paula, et al.
Publicado: (2023)

Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
por: López-Guerrero, José Antonio, et al.
Publicado: (2015)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Exosomes as mediators of platinum resistance in ovarian cancer
por: Crow, Jennifer, et al.
Publicado: (2017)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
por: Li, Siyu, et al.
Publicado: (2022)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
por: Havasi, Andrei, et al.
Publicado: (2023)

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
por: Gonzalez-Ochoa, Eduardo, et al.
Publicado: (2023)

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
por: Jones, M., et al.
Publicado: (1993)

Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1995)

COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer
por: Zhang, Hongqin, et al.
Publicado: (2022)

The Role of Oxidative Stress, Mitochondrial Function, and Autophagy in Diabetic Polyneuropathy
por: Sifuentes-Franco, Sonia, et al.
Publicado: (2017)

Platinum metals review.
Publicado: (1957)

Immunosuppression by Platinum Diamines
por: Berenbaum, M. C.
Publicado: (1971)

Uranium-Platinum System
por: Park, J. J., et al.
Publicado: (1960)

Alloying Platinum with Gold
por: Barton, J. Herbert
Publicado: (1906)

Chemistry of the Metals—Platinum
por: Wright, Reginald N.
Publicado: (1854)

Chemistry of the Metals—Platinum
por: Wright, Reginald N.
Publicado: (1854)

Observing the oxidation of platinum
por: van Spronsen, Matthijs A., et al.
Publicado: (2017)

Platinum Growing Scarce
Publicado: (1889)

Platinum and Gold Blocks
Publicado: (1883)

Cystic fluid-platinum kinetics in ovarian cancer patients: relevance to cis-dichlorodiammine platinum (II) sensitivity testing in vitro.
por: Shelley, M. D., et al.
Publicado: (1985)

Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
por: Kunos, Charles, et al.
Publicado: (2012)

Recovery of platinum(0) through the reduction of platinum ions by hydrogenase-displaying yeast
por: Ito, Rio, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gioeq8g90tg5nge61uee9miv5d